Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
Should CYP2C19 genotype testing be performed in patients presenting with ISR on Plavix?
Related Questions
During a coronary intervention, if the activated clotting time (ACT) is not within the therapeutic range despite administering weight-based unfractionated heparin, what alternative options do you consider?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
What is your preferred intervention for diffuse severe ISR involving two layers of stent?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
Would you favor culprit-only PCI, complete revascularization via percutaneous approach, or urgent CABG evaluation for a young diabetic patient with newly reduced LVEF < 35% presenting with an anterior STEMI and multivessel disease?
What is a reasonable protocol for how long to hold warfarin and/or DOACs before cardiac catheterization?
What neurologic and hemodynamic parameters do you use to determine candidacy for emergent cath lab activation following out of hospital cardiac arrest from VT/VF in patients with NSTEMI after ROSC has been achieved?
What would be your percutaneous approach to a severely stenotic bifurcation lesion with a large aneurysm post-stenosis?
What is your stepwise approach to managing no re-flow during PCI?
